Proteinuria induced by anti-vascular endothelial growth factors: two cases report and literature review

VernacularTitle:抗血管内皮生长因子类药物致蛋白尿2例及文献复习
Author: Yangmei XIE ¹ ; Wei LIN ; Liping CHEN ; Lijian TAO ; Ting MENG
Author Information

1. 中南大学湘雅医院肾内科，长沙　410008
Keywords: Antineoplastic agents; Carcinoma; Proteinuria; Thrombotic microangiopathy
From: Chinese Journal of Nephrology 2024;40(8):671-674
CountryChina
Language:Chinese
Abstract: This article reports two cases of proteinuria caused by anti-vascular endothelial growth factor (VEGF) drugs in the treatment of liver cancer and ovarian cancer, respectively. Hypertension, massive albuminuria and renal insufficiency occurred in the patient with liver cancer during the use of toripalimab/camrelizumab combined with lenvatinib and regorafenib, and urinary protein was 4.02 g/24 h. The patient with ovarian cancer developed hypertension, proteinuria and 1.13 g/24 h urinary protein during the use of bevacizumab. Renal biopsy showed thrombotic microangiopathy in the glomeruli of both patients. Anti-VEGF drugs-associated glomerular microangiopathy was considered. The patient with liver cancer had no improvement after halving the dose of lenvatinib, and the effect was not good after treatment with low-dose corticosteroids combined with renin-angiotensin-aldosterone system inhibitors. After stopping anti-VEGF drugs, the proteinuria in both patients turned negative.